Targeted Genetics deal

The Seattle company entered into three agreements under which it acquired exclusive rights to technologies using adeno-associated virus (AAV) vectors in gene therapy.

The NIH granted Targeted Genetics a license in cystic fibrosis covering an AAV vector capable of expression from a novel promoter. Johns Hopkins University granted a license to AAV technology, developed with the company, to produce AAV vectors for in vivo delivery. The company received rights from the Medical College of Ohio to methods for producing AAV vectors. ...